The categorisation of a company as large, mid or small cap is based on its market capitalisation. For a company to move upwards and into another segment, it needs to grow its market cap.
However, market cap is relative and based on overall market movement. Meaning that when the market rises, overall, the market cap cutoff also rises. So if a company grows and moves at the same pace as the market, they may not grow in terms of their categorisation.
In other words, for a company to move up the ranks — for example, from the small-cap to the mid-cap category — its stock must deliver exceptional outperformance. Conversely, significant underperformance can just as easily result in relegation to a lower category.
Not every company starts off with a huge market cap off the bat — most of them get there slowly and steadily. We’re looking at a few prominent large cap companies that started out in the small cap category, and outperformed the market over the years, to attain their present status. How they started, how they grew, and the key milestones that propelled them into the well-respected large caps they are today. This week’s company: pharmaceuticals giant Aurobindo Pharma.
How it started
Aurobindo Pharma was founded by PV Ramprasad Reddy and K Nityananda Reddy founded this company as a private limited entity in 1986. The company commenced operations in 1988 with a single unit in Pondicherry, manufacturing semi synthetic penicillins (SSPs). Today, they have a robust product portfolio spanning biosimilars, dermatology, injectables, vaccines, peptides and more. Here’s a breakdown of their growth journey.
*Generative AI via Napkin
2012 was a big year for APL on the Indian markets as well, being one of the biggest gainers on the Indian markets that year. took nearly 3 decades and significant expansion for APL to move from a publicly-listed small cap in 1992, and crossover into the midcap segment in 2012.
Key growth drivers and success factors
There are a few key milestones and successes that have catapulted Aurobindo Pharma into the big league.
Product portfolio: One of Aurobindo Parma’s strengths lies in its diverse product portfolio, where revenues are not heavily dependent on one segment or market of the business.
- The core segments include generic formulations that dominate its revenues, with a strong presence across therapeutic areas such as antibiotics, antiretrovirals (ARVs), cardiovascular, central nervous system (CNS) treatments, gastroenterology, and anti-allergy medications.
- APL also has a presence in high-value segments and is expanding into oncology, hormones, and biosimilars (a biological medicines that are highly similar to other, already-approved biological medicines), and advanced drug delivery platforms like inhalers, patches, films and depot injections (long acting injectables that release medication slowly, over an extended period after a single shot).
- Active Pharmaceutical Ingredients (APIs) contribute to a significant portion of APL’s business, making it more backward-integrated.
Aurobindo has a global presence across 150+ countries, with strong revenues from the USA and Europe, complemented by a growing share in emerging markets like Indonesia. So no single therapeutic area or market overwhelmingly dominates its revenues, making it relatively resilient as a company.
USFDA approvals: Aurobindo Pharma managed to secure several crucial USFDA approvals between 2012 and 2014. The US is a highly-regulated but lucrative market, and winning approvals is key to gaining market share.
Pharma companies need to file an ANDA (Abbreviated New Drug Application). ANDA approval allows a company to to launch a generic version of a branded drug in the US market. Usually, the first-to-file (or first-to-market) ANDAs capture significant market share quickly.
2012
Approvals for:
Amlodipine + Benazepril, generic of Lotrel, a antihypertensive drug
Escitalopram, a generic of Lexapor, an antidepressant
Modafinil, a generic of Provigil, drug for sleep disorders
2013:
Approvals for multiple ANDAs across therapeutic areas, touching 15 approvals by mid-2013
2014:
APL had 336 ANDAs filed as on March 2014, across a number of complex generics, including ARV and cardiovascular products, of which 155 had received final approval,
Gaining these approvals and expanding the product range across therapeutic areas (CNS, cardiovascular, ARVs) helped diversify revenues and improve margins for APL, unlocking access to multi‑billion‑dollar markets and setting the stage for APL’s later transition to large-cap status. This surge of approvals, especially for high-value cardiovascular, CNS, and sleep-disorder treatments, helped boost credibility in the US market. APL became a go‑to generic manufacturer for the US market, gaining pricing power and scale.
Global presence and Actavis acquisition: APL may be an Indian firm, but the domestic market is not the biggest contributor to its overall revenue. A bulk of APL’s business is in the global market, and a focus on penetrating foreign markets and establishing a global manufacturing presence is what helped APL achieve near-bluechip status.
While the first decade saw APL enter the US and a few markets within the EU (the acquisitions of Milpharm UK, TAD Italy, and Pharmacin Netherlands), the 2014 Actavis acquisition opened up several more new markets in the EU. (Actavis is a pharma company that develops and produces branded and generic drugs.)
In January 2014, Aurobindo signed a binding agreement to acquire Actavis’s generics operations across 7 Western Europe countries (France, Germany, Spain, Italy, Portugal, Belgium, Netherlands) for about €30 million. With the acquisition, APL expanded its product lines and distribution network. By April 1, 2014, the acquisition was completed, bringing an estimated €320 million in 2013 sales, 1,200 products, a 450+ INN (International Nonproprietary Name) portfolio, plus 200+ pipeline items. APL also got its foot in the door in a segment it hadn’t touched before, that of hospital sales. With the acquisition, 25% of the sales channels comprised of hospital sales, something APL leveraged for its injectables portfolio.
This move elevated Aurobindo into a real global pharmaceutical player, diversifying its revenue streams and strengthening its European footprint, pushing it into the large‑cap bracket by late 2014.
Between 2016 and 2022, Aurobindo Pharma continued to build on its growth momentum, achieving a series of significant milestones. The company entered the biosimilars and vaccines segment, marking its foray into complex biologics. It also filed its first peptide DMF, reinforcing its focus on differentiated products. To expand its presence in Europe, Aurobindo acquired Generis in Portugal, gaining access to new markets and bolstering its capabilities in differentiated technology platforms and specialty pharmaceuticals.
In the United States, it commissioned a fully-automated distribution center, strengthening its supply chain and operational efficiency. Meanwhile, the company began setting up a manufacturing facility in Taizhou, China, to support global production needs. To broaden its consumer healthcare offerings, Aurobindo acquired 9 over-the-counter brands in 2021, and entered the domestic market in 2022 through the acquisition of Veritaz Healthcare Limited.
Aurobindo Pharma today – and beyond
By 2022, 40 years after going public, APL officially became a net cash company. As of 2025, Aurobindo Pharma is one of the top ten generic pharmaceutical companies globally, and the largest Indian generic company with US sales. It operates as a fully integrated, large-scale pharmaceutical enterprise across six key therapeutic areas: antibiotics, anti-retrovirals, cardiovascular treatments, central nervous system medications, gastroenterology, and anti-allergy products.
Its products are available in over 155 countries, with ongoing expansion efforts in new markets such as Poland, Italy, Spain, the Czech Republic, Portugal, and France. Aurobindo’s marketing partners include prominent multinational pharma giants like AstraZeneca and Pfizer.
Aurobindo’s key focus now is becoming more self-reliant, investing in R&D, and expanding its global footprint and entering new markets and segments. In 2023, the company forayed into Indonesia with the acquisition of 15 brands from Vitaris/Pfizer Inc Indonesia. In 2024, APL completed its acquisition of Hyderabad-based GLS Pharma (51% was acquired in 2022), a leading oncology player.
And today, the company remains on a strong growth path, strengthening its presence in specialty segments and broadening its portfolio with high-value offerings across oncology, hormones, and biosimilars, as well as advanced drug delivery platforms such as depot injections, inhalers, patches, and films.
Glossary
ANDA stands for Abbreviated New Drug Application. It’s a specific type of application submitted to the U.S. Food and Drug Administration (FDA) for the approval of a generic drug.
ARV stands for antiretroviral, which refers to drugs used to treat or prevent infections caused by retroviruses, most notably HIV
API stands for Active Pharmaceutical Ingredient. It refers to the biologically active component of a drug that produces the intended therapeutic effect. Essentially, it’s the specific substance in a medication that makes it work.
Sources
Capital Market: Aurobindo Pharma
Economic Times: Aurobindo Pharma Acquires Italian Company
Business Standard: Aurobindo Pharma in Pact with AstraZeneca
Aurobindo Acquisition of Actavis Western EU Commercial Operations
Aurobindo Pharma Limited Annual Report 2023-24
Aurobindo Pharma Investor Presentation March 2025
Aurobindo Pharma Investor Presentation May 2025